Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women

International Journal of Tissue Reactions

Volumn 25, Issue 2, 2003, Pages 73-78

  D'Amelio, P ^a   Muratore, M ^b   Tinelli, F ^c   Tamone, C ^a   Cosentino, L ^b   Quarta, E ^b   Calcagnile, F ^b   Carlo Isaia, G ^a   Maggiani, G ^d  

^a UNIVERSITY OF TURIN   (Italy)

^b First Division of Pneumology   (Italy)

^c VITO FAZZI HOSPITAL   (Italy)

^d Società Prodotti Antibiotici   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CALCIUM; CLODRONIC ACID; COLECALCIFEROL; OSTEOCALCIN; PROCOLLAGEN AMINOPEPTIDE; PROCOLLAGEN C TELOPEPTIDE; RALOXIFENE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE TURNOVER; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; HOT FLUSH; HUMAN; INJECTION PAIN; LUMBAR VERTEBRA; MONOTHERAPY; OSTEOBLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; VASOMOTOR DISORDER;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; BONE RESORPTION; CHOLECALCIFEROL; CLODRONIC ACID; DENSITOMETRY, X-RAY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0141495418     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet, 348, 1535, 1996.
2. Black D.M., Thompson D.E., Bauer D.C., et al. Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J. Clin. Endocrinol. Metab., 85(11), 4118, 2000.
3. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA, 282(14), 1344, 1999.
4. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N. Engl. J. Med., 344(5), 333, 2001.
5. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA, 282(7), 637, 1999.
6. Johnston C.C. Jr., Bjarnason N.H., Cohen F.J., et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: Three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch. Intern. Med., 160(22), 3444, 2000.
7. Coxon F.P., Helfrich M.H., Van't Hof R., et al. Protein geranyl granulation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J. Bone. Miner. Res., 15(8), 1467, 2000.
8. Van Beek E.R., Lowik C.W., Papapoulos S.E. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: The role of protein geranyl granulation in the action of nitrogen containing bisphosphonates on osteoclast precursors. Arthritis Rheum, 44(9), 2201, 2001.
9. Frith J.C., Monkkonen J., Auriola S., Monkkonen H., Rogers M.J. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Bone, 30(1), 64, 2002.
10. McCloskey E.V., Dunn J.A., Kanis J.A., MacLennan I.C., Drayson M.T. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br. J. Haematol., 113(4), 1035, 2001.
11. Bone H.G., Greenspan S.L., McKeever C. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J. Clin. Endocrinol. Metab., 85(2), 720, 2000.
12. Lindsay R., Cosman F., Lobo R.A., et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial. J. Clin. Endocrinol. Metab., 84, 3076, 1999.
13. Wimalawansa S.J. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. Am. J. Med., 104, 219, 1998.
14. Wimalawansa S.J. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: Four year randomized study. Am. J. Med., 99, 35, 1995.
15. Harris S.T., Eriksen E.F., Davidson M., et al. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab., 86(5), 1890, 2001.
16. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin. Oncol., 28(4 Suppl. 11), 49, 2001.
17. D'Aoust P., McCulloch C.A., Tenenbaum H.C., Lekic P.C. Etidronate (HEBP) promotes osteoblast differentiation and wound closure in rat calvaria. Cell. Tissue Res., 302(3), 353, 2000.
18. Mathov I., Plotkin L.I., Sgarlata C.L., Leoni J., Bellido T. Extracellular signal-regulated kinases and calcium channels are involved in the proliferative effect of bisphosphonates on osteoblastic cells in vitro. J. Bone Miner. Res., 16(11), 2050, 2001.
19. Reinholz G.G., Getz B., Pederson L., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res., 60(21), 6001, 2001.